BioAtla 公司被允许继续在纳斯达克上市，但需满足一定条件；必须在 2026 年初前达到股权和出价价格的要求
BioAtla Inc. has been granted continued listing on Nasdaq with conditions after presenting a compliance plan to the Hearing Panel. The company must meet specific equity and bid price requirements by December 31, 2025, and February 2, 2026, respectively. BioAtla has applied to transfer to The Nasdaq Capital Market as part of its efforts to regain compliance.
BioAtla Inc. is undergoing an ongoing delisting process from The Nasdaq Stock Market due to not meeting specific minimum requirements. The company presented a compliance plan to Nasdaq’s Hearing Panel on September 9, 2025, outlining steps to regain compliance. The Panel granted BioAtla’s request for continued listing, contingent on meeting certain conditions. BioAtla has already applied to transfer to The Nasdaq Capital Market as of September 18, 2025. The company aims to meet the necessary stockholder equity and bid price criteria by December 31, 2025, and February 2, 2026, respectively. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-211305), on September 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
